



EIZO Corporation
Hiroaki Hashimoto
Senior Manager of Regulatory Compliance and Safety Department
153 Shimokashiwano
HAKUSAN, ISHIKAWA, 924-8566
JAPAN

July 16, 2024

Re: K241441

Trade/Device Name: RadiForce RX670; RadiForce RX670-AR
Regulation Number: 21 CFR 892.2050
Regulation Name: Medical Image Management And Processing System
Regulatory Class: Class II
Product Code: PGY
Dated: May 22, 2024
Received: May 22, 2024

Dear Hiroaki Hashimoto:

We have reviewed your section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (the Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. Although this letter refers to your product as a device, please be aware that some cleared products may instead be combination products. The 510(k) Premarket Notification Database available at <https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm> identifies combination product submissions. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Additional information about changes that may require a new premarket notification are provided in the FDA guidance documents entitled "Deciding When to Submit a 510(k) for a Change to an Existing Device" (<https://www.fda.gov/media/99812/download>) and "Deciding When to Submit a 510(k) for a Software Change to an Existing Device" (<https://www.fda.gov/media/99785/download>).

Your device is also subject to, among other requirements, the Quality System (QS) regulation (21 CFR Part 820), which includes, but is not limited to, 21 CFR 820.30, Design controls; 21 CFR 820.90, Nonconforming product; and 21 CFR 820.100, Corrective and preventive action. Please note that regardless of whether a change requires premarket review, the QS regulation requires device manufacturers to review and approve changes to device design and production (21 CFR 820.30 and 21 CFR 820.70) and document changes and approvals in the device master record (21 CFR 820.181).

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR Part 803) for devices or postmarketing safety reporting (21 CFR Part 4, Subpart B) for combination products (see <https://www.fda.gov/combination-products/guidance-regulatory-information/postmarketing-safety-reporting-combination-products>); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820) for devices or current good manufacturing practices (21 CFR Part 4, Subpart A) for combination products; and, if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR Parts 1000-1050.

Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to <https://www.fda.gov/medical-devices/medical-device-safety/medical-device-reporting-mdr-how-report-medical-device-problems>.

For comprehensive regulatory information about medical devices and radiation-emitting products, including information about labeling regulations, please see Device Advice (<https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatory-assistance>) and CDRH Learn (<https://www.fda.gov/training-and-continuing-education/cdrh-learn>). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (<https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatory-assistance/contact-us-division-industry-and-consumer-education-dice>) for more information or contact DICE by email (DICE@fda.hhs.gov) or phone (1-800-638-2041 or 301-796-7100).

Sincerely,



Jessica Lamb

Assistant Director

DHT8B: Division of Radiologic Imaging

Devices and Electronic Products

OHT8: Office of Radiological Health

Office of Product Evaluation and Quality

Center for Devices and Radiological Health

Enclosure

Indications for Use

Submission Number (if known)

K241441

Device Name

RadiForce RX670;
RadiForce RX670-AR

Indications for Use (Describe)

This Product is indicated for use in displaying radiological images for review, analysis, and diagnosis by trained medical practitioners. The display is not intended for mammography.

Type of Use (Select one or both, as applicable)



Prescription Use (Part 21 CFR 801 Subpart D)



Over-The-Counter Use (21 CFR 801 Subpart C)

CONTINUE ON A SEPARATE PAGE IF NEEDED.

This section applies only to requirements of the Paperwork Reduction Act of 1995.

DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.

The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:

Department of Health and Human Services
Food and Drug Administration
Office of Chief Information Officer
Paperwork Reduction Act (PRA) Staff
PRASaff@fda.hhs.gov

"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."



EIZO Corporation, 153 Shimokashiwano, Hakusan, Ishikawa
924-8566 Japan

U.S. Food and Drug Administration
Center for Devices and Radiological Health

Name	Hiroaki Hashimoto
Department	Regulatory Compliance and Safety
Telephone	+81 (76) 274-2468
E-Mail	hiroaki.hashimoto@eizo.com

510(k) Summary K241441

1. Submitter

EIZO Corporation
153 Shimokashiwano, Hakusan,
Ishikawa 924-8566 Japan
Phone: +81 (76) 274-2468
Contact Person: Hiroaki Hashimoto
Date of Prepared: May 20th, 2024

2. Device

- Name of Device: RadiForce RX670; RadiForce RX670-AR
- Common or Usual Name: 30.0 inch (76.2 cm) Color LCD Monitor
- Classification Name: Medical Image Management and Processing System
(21 CFR 892.2050)
- Regulatory Class: II
- Product Code: PGY

3. Predicate Device

- Name of Device: RadiForce RX660, RX660-AR (K163335)
- Common or Usual Name: 6MP Color LCD Monitor
- Classification Name: Medical Image Management and Processing System
(21 CFR 892.2050)
- Regulatory Class: II
- Product Code: PGY
- Name of Device: RadiForce RS340 (K143098)
- Common or Usual Name: 3MP Color LCD Monitor
- Classification Name: Medical Image Management and Processing System
(21 CFR 892.2050)
- Regulatory Class: II
- Product Code: PGY

4. Device Description

RadiForce RX670 is a color LCD monitor for viewing medical images other than those of mammography. The color panel employs in-plane switching (IPS) technology allowing wide viewing angles and the matrix size (or resolution) is 3,280 x 2,048 pixels (6MP) with a pixel pitch of 0.1986 mm.

Since factory calibrated display modes, each of which is characterized by a specific tone curve (including DICOM GSDF), a specific luminance range and a specific color temperature, are stored in lookup tables within the monitor, the tone curve is e.g. DICOM compliant regardless of the display controller used. This helps ensure tone curves even if a display controller or workstation must be replaced or serviced.

There are two model variations, RX670 and RX670-AR. The difference of the two variations is the surface treatment of the display screens; the surface treatment of the RX670 is Anti-Glare (AG) treatment and that of the RX670-AR is Anti-Reflection (AR) coating.

RadiCS is application software to be installed in each workstation offering worry-free quality control of diagnostic monitors including the RadiForce RX670 based on the QC standards and guidelines and is capable of quantitative tests and visual tests defined by them. The RadiCS is included in this 510(k) submission as an accessory to the RadiForce RX670.

RadiCS is Basic Documentation level and that it's being used unchanged from the predicate software. RadiCS supports the functions of the monitor RadiForce RX670 and it's not a medical imaging software.

5. Indications for use

This Product is indicated for use in displaying radiological images for review, analysis, and diagnosis by trained medical practitioners. The display is not intended for mammography.

6. Comparison of Technological Characteristics with the predicate device

The comparison table below enumerates information derived from the product brochure and measured values of the each device and different technological characteristics are discussed in it:

Attributes	Proposed Device: RadiForce RX670	Predicate Device: RadiForce RX660
Indications for Use		
	This Product is indicated for use in displaying radiological images for review, analysis, and diagnosis by trained medical practitioners. The display is not intended for mammography.	This product is intended to be used in displaying and viewing digital images for review, analysis and diagnosis by trained medical practitioners. It does not support the display of mammography images for diagnosis.
Display Technology		
	TFT Color LCD Panel (IPS)	TFT Color LCD Panel (IPS)
Screen size		
	76.2cm / 30.0" Aspect ratio: 16 : 10	76.0cm / 30.0" Aspect ratio: 16 : 10
Backlight type		
	LED	LED
Frame rate and refresh rate		
Digital Scanning Frequency (H / V)	31 - 127 kHz / VGA TEXT: 69 - 71Hz, Except VGA TEXT:59 - 61Hz, Frame synchronous mode: 59 - 61 Hz	31 - 127 kHz / 22 - 61Hz (DVI), 29 - 61Hz (DisplayPort), VGA TEXT: 69 - 71Hz (DVI, DisplayPort) Frame synchronous mode: 29.5 – 30.5 Hz, 59 - 61 Hz
Display Interface		
Input video signals	USB Type-C (DisplayPort Alt Mode) x 1, DisplayPort x 2, HDMI x 1	DVI-D (dual link) x 1, DisplayPort x 2
Output video signals	USB Type-C (daisy chain) x 1	DisplayPort x 1 (daisy chain)
Video bandwidth		
	(HDMI) 25-440MHz (DisplayPort) 25-440MHz (DisplayPort Alt Mode Input(on USB Type-C))	(DVI) Single Display: Except LM derivation: 25- 240MHz LM derivation: 25-280MHz Up to 165MHz: Single Link Over 165MHz: Dual Link PbyP/PinP: 25-240MHz

	25-440MHz	Up to 165MHz: Single Link Over 165MHz: Dual Link (DisplayPort) DP1 Port Single Display: 25-440MHz PbyP/PinP: 25-240MHz DP2 Port: 25-240MHz
Ambient light sensing		
Ambient light sensor	Photo Diode Position: In the upper bezel of the screen Software tool: RadiCS	Photo Diode Position: In the upper bezel of the screen Software tool: RadiCS
Luminance calibration tools		
	Integrated optical sensor External optical sensor Calibration software: RadiCS	Integrated optical sensor External optical sensor Calibration software: RadiCS
Quality-control procedures		
	Software: RadiCS	Software: RadiCS

It is clear that the technological characteristics differences discussed above do not affect the safety and the effectiveness of the RX670.

7. Performance Testing

The bench tests below were performed on the RadiForce RX670 following the instructions in “*Guidance for Industry and FDA Staff: Display Devices for Diagnostic Radiology*” issued on September 28, 2022:

- Measurement of spatial resolution expressed as modulation transfer function (MTF)
- The maximum number allowed for each type of pixel defects/faults
- Visual check of presence or absence of miscellaneous artifacts on the display screen as specified in TG18 guideline
- Measurement of temporal response
- Measurement of Luminance
- Verification of the conformance to DICOM GSDF as specified in *Assessment of Display Performance for Medical Imaging Systems* by AAPM Task Group 18 (TG18 guideline)
- Measurement of Color tracking

The test results showed that the RadiForce RX670 has display characteristics equivalent to those of the predicate device, RadiForce RX660.

Besides, the display characteristics of the RadiForce RX670 meet the pre-defined criteria when criteria are set.

No animal or clinical testing was performed on the RadiForce RX670.

8. Conclusion

The RadiForce RX670 was determined to be substantially equivalent to the predicate device due to the following reasons:

- The stated intended use is substantially the same as that of the predicate device.
- It was confirmed that the technological characteristics differences from those of the predicate device do not affect the safety or the effectiveness.
- The bench tests demonstrated that the display characteristics are equivalent to those of the predicate device.